There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Globus Medical (GMED – Research Report) and ...

Globus Medical (NYSE:GMED – Free Report) had its target price increased by Canaccord Genuity Group from $92.00 to $101.00 in ...

In a report released today, Matt Miksic from Barclays maintained a Buy rating on Globus Medical (GMED – Research Report), with a price target ...

Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced preliminary unaudited sales results for the ...

Globus Medical Inc (GMED) stock saw a modest uptick, ending the day at $87.07 which represents a slight increase of $0.52 or 0.60% from the prior close of $86.55. The stock opened at $88.5 and touched ...

BofA analyst Craig Bijou upgraded Globus Medical (GMED) to Neutral from Underperform with a price target of $97, up from $80, ...

Shares of Globus Maritime (GLBS) were trading marginally in the green on Tuesday after the company announced it has closed a ...

Needham & Company LLC reissued their hold rating on shares of Globus Medical (NYSE:GMED – Free Report) in a research note published on Thursday,Benzinga reports. Several other brokerages have also ...

This leading medical device maker is showing constructive action in a flat base and setting up for its next move.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

在其他近期新闻中，Globus Medical因其强劲的第四季度收入和积极的2025年展望而受到各方分析师的关注。公司报告第四季度销售额为6.57亿美元，超过了市场预期。2024年全年销售额也大幅增长，达到约25.2亿美元。

周五，Canaccord Genuity维持了对Globus Medical (NYSE:GMED)股票的买入评级，并将目标价从之前的$92上调至$101。 这一调整是在公司宣布2024年第四季度初步业绩超过Canaccord Genuity和华尔街预期之后做出的。Canaccord Genuity的分析师根据这些结果和Globus Medical提供的2025年收入指引更新了他们的模型。